8-K: IKENA ONCOLOGY Announces 1-for-12 Reverse Stock Split and Rebranding to ImageneBio Ahead of Merger

Ikena Oncology, Inc. will effect a 1-for-12 reverse stock split, change its name to ImageneBio, Inc., and trade under the new ticker symbol IMA on Nasdaq, effective July 28, 2025, in anticipation of a proposed merger.

Summary

• Ikena Oncology, Inc. will implement a 1-for-12 reverse stock split of its common stock.
• The common stock is expected to begin trading on a post-reverse stock split basis on The Nasdaq Capital Market (Nasdaq) on July 28, 2025.
• The company will operate under the new name ImageneBio, Inc. and new ticker symbol IMA, with CUSIP 45175G207 and ISIN US45175G2075.
• The reverse stock split applies to all issued and outstanding shares of common stock.
• The number of issued and outstanding shares will decrease from approximately 48.2 million to approximately 4 million.
• The number of authorized common stock shares will not be affected by the reverse stock split.
• No fractional shares will be issued; stockholders will receive a cash payment equal to the fractional share multiplied by the closing price on July 24, 2025.
• Proportionate adjustments will be made to exercise prices and share numbers for outstanding equity awards.
• The par value per share ($0.001) will remain unchanged.
• Computershare is acting as the exchange agent for the reverse stock split.
• Stockholders holding shares in book-entry form or in brokerage accounts do not need to take action.
• The reverse stock split is being effected in anticipation of a proposed merger.

Sentiment

Score: 3

Explanation: While the reverse split and rebranding are presented as part of a strategic merger, a reverse split itself is generally a negative signal, often indicating a need to maintain listing compliance due to a low stock price. The numerous risks associated with the merger and financing also contribute to a cautious outlook.

Positives

• The reverse stock split aims to increase the per-share price, potentially helping the company maintain its Nasdaq listing compliance.
• The rebranding to ImageneBio, Inc. and ticker change signal a new strategic direction and identity for the combined entity post-merger.

Negatives

• A reverse stock split is often a measure taken by companies whose stock price has fallen significantly, indicating potential financial distress or lack of investor confidence.
• Shareholders will own fewer shares, though their percentage ownership remains the same (before fractional share cash-out).
• Cash payment for fractional shares means some shareholders will have a small portion of their investment liquidated.

Risks

• Conditions to the closing of the proposed merger may not be satisfied, or one party may terminate the Merger Agreement.
• Uncertainties exist regarding the timing of the consummation of the proposed merger and concurrent financing.
• Uncertainties exist regarding the timing or consummation of the reverse stock split.
• Adjustments to the exchange ratio could result in Ikena stockholders and Inmagene shareholders owning more or less of the combined company than currently anticipated.
• Risks are related to the mechanics for conducting a reverse stock split.
• Unexpected costs, charges, or expenses may result from the transaction.
• Potential adverse reactions or changes to business relationships may result from the announcement or completion of the proposed merger or reverse stock split.
• Uncertainties are associated with Inmagene's platform technologies, clinical development, and regulatory approval of product candidates, including potential delays in clinical trials.
• There is a risk that the combined company will be unable to obtain sufficient additional capital to continue to advance product candidates and preclinical programs.
• Uncertainties exist in obtaining successful clinical results for product candidates and unexpected costs that may result therefrom.
• Risks are related to the failure to realize any value from product candidates and preclinical programs being developed due to inherent risks and difficulties in successfully bringing product candidates to market.
• Possible failure to realize certain anticipated benefits of the proposed merger, concurrent financing, or reverse stock split, including with respect to future financial and operating results.
• Risks are associated with Ikena's financial close process.
• The Ikena concurrent financing may not be consummated.
• There is potential for the occurrence of any event, change, or other circumstance or condition that could give rise to the termination of the Merger Agreement and any agreements entered into in connection therewith.
• Contingent value rights holders of Ikena and Inmagene may never receive any proceeds pursuant to their respective contingent value rights agreements.

Future Outlook

The combined company, ImageneBio, Inc., anticipates future operations focused on the development and commercial potential of IMG-007 and any other product candidates or platform technologies. Expected preclinical and clinical drug development activities and related timelines, including the expected timing for data and other clinical results, are part of the forward outlook. There is also an expectation of potentially receiving proceeds pursuant to the contingent value rights agreements of Ikena and Inmagene Biopharmaceuticals.

Management Comments

• The company will effect a 1-for-12 reverse stock split of its common stock, expected to begin trading on a post-reverse stock split basis on Nasdaq on July 28, 2025, under the new name ImageneBio, Inc. and ticker symbol IMA.
• The reverse stock split will reduce the number of issued and outstanding common shares from approximately 48.2 million to approximately 4 million.
• The number of authorized common stock shares will not be affected by the reverse stock split.
• No fractional shares will be issued; instead, stockholders will receive a cash payment in lieu of such fractional share, calculated based on the closing price on July 24, 2025.
• Proportionate adjustments will be made to the exercise prices and number of shares underlying outstanding equity awards.
• There will be no change to the par value per share.
• Stockholders holding shares in book-entry form or in brokerage accounts need not take any action in connection with the reverse stock split.

Industry Context

The biotechnology and pharmaceutical industries frequently see mergers and corporate restructuring, especially among smaller, clinical-stage companies. Reverse stock splits are common for companies seeking to maintain stock exchange listing compliance, particularly in sectors where early-stage companies may experience prolonged periods without significant revenue or profitability, leading to low stock prices. The rebranding suggests a strategic pivot or fresh start, often accompanying mergers to signify a new combined entity and vision.

Stakeholder Impact

• Shareholders will experience a 1-for-12 reduction in the number of shares held, with cash payment for fractional shares. Their percentage ownership will remain proportionate (before fractional share cash-out). The stock will trade under a new name and ticker.

Next Steps

• Trading on a post-reverse stock split basis under the new name ImageneBio, Inc. and ticker IMA on Nasdaq, expected July 28, 2025.
• Consummation of the proposed merger.
• Consummation of the concurrent financing.
• Future operations of the combined company, including development of IMG-007 and other product candidates.
• Anticipated preclinical and clinical drug development activities and related timelines, including expected timing for data and other clinical results.
• Potential receipt of proceeds from contingent value rights agreements.

Key Dates

Recommendation

The reverse stock split is a defensive measure to maintain Nasdaq listing compliance, often signaling underlying challenges. However, it is explicitly tied to a proposed merger with Inmagene Biopharmaceuticals and a concurrent financing, which could represent a strategic pivot and a new path forward for the combined entity, ImageneBio. The success of this strategy, particularly the clinical development of IMG-007 and the securing of additional capital, is highly uncertain as highlighted by the extensive risk factors. Given the significant uncertainties and the transformative nature of the merger, a 'hold' recommendation is appropriate for existing investors to observe the integration and initial performance of the combined entity. New investors should exercise caution and await further clarity on the combined company's financial position and pipeline progress.

Keywords

Ikena Oncology, ImageneBio, reverse stock split, merger, Nasdaq, ticker change, biotechnology, oncology, pharmaceutical, corporate action, capital market, common stock, CUSIP, ISIN, IMG-007, Inmagene Biopharmaceuticals, corporate governance